Skip navigation

Phosphate salts


What is it?

Phosphate salts refers to many different combinations of the chemical phosphate with salts and minerals. Foods high in phosphate include dairy products, whole grain cereals, nuts, and certain meats. Phosphates found in dairy products and meats seem to be more easily absorbed by the body than phosphates found in cereal grains. Cola drinks contain a lot of phosphate - so much, in fact, that they can cause too much phosphate in the blood.

People use phosphate salts for medicine. Be careful not to confuse phosphate salts with substances such as organophosphates, or with tribasic sodium phosphates and tribasic potassium phosphates, which are very poisonous.

Phosphate salts are taken by mouth for treating blood phosphate levels that are too low and blood calcium levels that are too high, and for preventing kidney stones. They are also taken for treating osteomalacia (often called “rickets” in children), a condition caused by a mineral imbalance in the body that leads to softening of the bones. Phosphate salts are also used for improving exercise performance, as an antacid for gastroesophageal reflux disease (GERD), and as a laxative for emptying the bowels before surgery.

Phosphate salts and calcium are applied to sensitive teeth to reduce pain.

Rectally, phosphate salts are used as a laxative to clean the bowels before surgery or intestinal tests.

Healthcare providers sometimes give potassium phosphate intravenously (by IV) for treating low phosphate and high calcium levels in the blood, and for preventing low phosphate in patients who are being tube-fed.

How effective is it?

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.

The effectiveness ratings for PHOSPHATE SALTS are as follows:

Effective for...

  • Correcting low blood phosphate levels, when sodium and potassium phosphates are taken by mouth or given intravenously (by IV) by a healthcare provider.

Likely effective for...

  • Correcting high blood calcium levels, when sodium and potassium phosphates are used.

Possibly effective for...

  • Preventing some types of kidney stones.

Likely ineffective for...

  • Improving aerobic exercise performance.

Insufficient evidence to rate effectiveness for...

  • Sensitive teeth.
  • Heartburn.
  • Cleaning out the bowels as a laxative preparation for intestinal tests such as colonoscopy when sodium phosphates are used.
  • Other conditions.
More evidence is needed to rate the effectiveness of phosphate salts for these uses.

How does it work?

Return to top
Phosphates are normally absorbed from food and are important chemicals in the body. They are involved in cell structure, energy transport and storage, vitamin function, and numerous other processes essential to health. Phosphate salts can act as laxatives by causing more fluid to be drawn into the intestines and stimulating the gut to push out its contents faster.

Are there safety concerns?

Return to top
Phosphate salts containing sodium, potassium, aluminum, or calcium seem to be safe for most people when used occasionally or short-term. Phosphate intake (expressed as phosphorus) should not be more than 4 grams per day for adults younger than 70 years of age and 3 grams per day for people who are older.

Regular long-term use can upset the balance of phosphates and other chemicals in the body and should be monitored by a healthcare professional to avoid serious side effects. Phosphate salts can irritate the digestive tract and cause stomach upset, diarrhea, constipation, and other problems.

Do not confuse phosphate salts with substances such as organophosphates, or with tribasic sodium phosphates and tribasic potassium phosphates, which are very poisonous.

Special precautions & warnings:

Pregnancy and breast-feeding: Phosphate salts from dietary sources are LIKELY SAFE for pregnant or breast-feeding women when used at the recommended allowances of 1250 mg daily for mothers between 14-18 years of age and 700 mg daily for those over 18 years of age. Other amounts should only be used with the advice and ongoing care of a healthcare professional.

Children: Phosphate salts are LIKELY SAFE for children when used at the recommended daily allowances of 460 mg for children 1-3 years of age; 500 mg for children 4-8 years of age; and 1250 mg for children 9-18 years of age. Phosphate salts can be UNSAFE if phosphate consumed (expressed as phosphorous) exceeds the tolerable upper intake level (UL). The ULs are 3 grams per day for children 1-8 years; and 4 grams per day for children 9 years and older.

Heart disease: Avoid using phosphate salts that contain sodium if you have heart disease.

Fluid retention (edema): Avoid using phosphate salts that contain sodium if you have cirrhosis, heart failure, or other conditions that can cause edema.

High levels of calcium in the blood (hypercalcemia): Use phosphate salts cautiously if you have hypercalcemia. Too much phosphate could cause calcium to be deposited where it shouldn’t be in your body.

High levels of phosphate in the blood: People with Addison's disease, severe heart and lung disease, kidney disease, thyroid problems, or liver disease are more likely than other people to develop too much phosphate in their blood when they take phosphate salts. Use phosphate salts only with the advice and ongoing care of a healthcare professional if you have one of these conditions.

Kidney disease: Use phosphate salts only with the advice and ongoing care of a healthcare professional if you have kidney problems.

Are there interactions with medications?

Return to top

Moderate

Be cautious with this combination.

Bisphosphonates
Bisphosphonate medications and phosphate salts can both lower calcium levels in the body. Taking large amounts of phosphate salts might cause calcium levels to become too low.

Some bisphosphonates include alendronate (Fosamax), etidronate (Didronel), risedronate (Actonel), tiludronate (Skelid), and others.

Are there interactions with herbs and supplements?

Return to top
Calcium, iron, and magnesium
Phosphate can combine with calcium, iron, or magnesium. This reduces the body's ability to absorb phosphate, calcium, iron, and magnesium. To avoid this interaction, phosphate should be taken at least 2 hours before or after taking calcium, iron, or magnesium.

Are there interactions with foods?

Return to top
There are no known interactions with foods.

What dose is used?

Return to top
The following doses have been studied in scientific research:

BY MOUTH:
  • For raising phosphate levels that are too low or lowering calcium levels that are too high: Healthcare providers measure the levels of phosphate and calcium in the blood and give just enough phosphate to correct the problem.
As a supplement, the recommended daily dietary allowances (RDAs) of phosphate (expressed as phosphorus) are: Children 1-3 years, 460 mg; children 4-8 years, 500 mg; men and women 9-18 years, 1250 mg; men and women over 18 years, 700 mg.

The adequate intakes (AI) for infants are: 100 mg for infants 0-6 months old and 275 mg for infants 7-12 months of age.

Tolerable Upper Intake Levels (UL), the highest intake level at which no unwanted side effects are expected, for phosphate (expressed as phosphorus) per day are: children 1-8 years, 3 grams per day; children and adults 9-70 years, 4 grams; adults older than 70 years, 3 grams; pregnant women 14-50 years, 3.5 grams; and breast-feeding women 14-50 years, 4 grams.

Other names

Return to top
Aluminum phosphate, Bone Phosphate, Calcium phosphate, Calcium Orthophosphate, Calcium Phosphate Dibasic Anhydrous, Calcium Phosphate-Bone Ash, Calcium Phosphate Dibasic Dihydrate, Calcium Phosphate Dibasique Anhydre, Calcium Phosphate Dibasique Dihydrate, Calcium Phosphate Tribasic, Calcium Phosphate Tribasique, Dibasic Calcium Phosphate Dihydrate, Di-Calcium Phosphate, Dicalcium Phosphate, Dicalcium Phosphates, Neutral Calcium Phosphate, Orthophosphate de Calcium, Phosphate d’Aluminium, Phosphate de Calcium, Phosphate de Magnésium, Phosphate Neutre de Calcium, Phosphate d’Os, Phosphate Tricalcium, Precipitated Calcium Phosphate, Précipitation du Phosphate de Calcium, Précipité de Phosphate de Calcium, Tertiary Calcium Phosphate, Tricalcium Phosphate, Whitlockite, Magnesium Phosphate, Merisier, Potassium phosphate, Dibasic Potassium Phosphate, Dipotassium Hydrogen Orthophosphate, Dipotassium Monophosphate, Dipotassium Phosphate, Monobasic Potassium Phosphate, Potassium Acid Phosphate, Potassium Biphosphate, Potassium Dihydrogen Orthophosphate, Potassium Hydrogen Phosphate, Phosphate de Dipotassium, Phosphate d’Hydrogène de Potassium, Phosphate de Potassium, Phosphate de Potassium Dibasique, Phosphate de Potassium Monobasique, Sodium phosphate, Anhydrous Sodium Phosphate, Dibasic Sodium Phosphate, Disodium Hydrogen Orthophosphate, Disodium Hydrogen Orthophosphate Dodecahydrate, Disodium Hydrogen Phosphate, Disodium Phosphate, Phosphate of Soda, Sales de Fosfato, Sels de Phosphate, Sodium Orthophosphate, Orthophosphate Disodique d’Hydrogène, Phosphate Disodique d’Hydrogène, Orthophosphate de Sodium, Phosphate de Sodium Anhydre, Phosphate de Sodium Dibasique.

Methodology

Return to top
To learn more about how this article was written, please see the Natural Medicines Comprehensive Database methodology.methodology (http://www.nlm.nih.gov/medlineplus/druginfo/natural/methodology.html).

References

Return to top
To see all references for the Phosphate salts page, please go to http://www.nlm.nih.gov/medlineplus/druginfo/natural/735.html.

  1. Finkelstein JS, Klibanski A, Arnold AL, et al. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA 1998;280:1067-73. View abstract.
  2. Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: A randomized controlled study comparing parathyroid hormone (1-34) versus calcitriol and calcium. J Clin Endocrinol Metab 2003;88:4214-20. View abstract.
  3. Lindsay R, Nieves J, Formica C, et al. Randomized controlled study of the effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5. View abstract.
  4. Winer KK, Yanovski JA, Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 1996;276:631-6. View abstract.
  5. Leung AC, Henderson IS, Halls DJ, Dobbie JW. Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia. Br Med J (Clin Res Ed) 1983;286:1379-81. View abstract.
  6. Roxe DM, Mistovich M, Barch DH. Phosphate-binding effects of sucralfate in patients with chronic renal failure. Am J Kidney Dis 1989;13:194-9. View abstract.
  7. Hergesell O, Ritz E. Phosphate binders on iron basis: a new perspective? Kidney Intl Suppl 1999;73:S42-5. View abstract.
  8. Peters T, Apt L, Ross JF. Effect of phosphates upon iron absorption studied in normal human subjects and in an experimental model using dialysis. Gastroenterology 1971;61:315-22. View abstract.
  9. Monsen ER, Cook JD. Food iron absorption in human subjects IV. The effects of calcium and phosphate salts on the absorption of nonheme iron. Am J Clin Nutr 1976;29:1142-8. View abstract.
  10. Lindsay R, Nieves J, Henneman E, et al. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 1993;77:1535-9. View abstract.
  1. Campisi P, Badhwar V, Morin S, Trudel JL. Postoperative hypocalcemic tetany caused by Fleet Phospho-Soda preparation in a patient taking alendronate sodium. Dis Colon Rectum 1999;42:1499-501. View abstract.
  2. Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf 2003;26:1093-115. View abstract.
  3. Schiller LR, Santa Ana CA, Sheikh MS, et al. Effect of the time of administration of calcium acetate on phosphorus binding. New Engl J Med 1989;320:1110-3. View abstract.
  4. Saadeh G, Bauer T, Licata A, Sheeler L. Antacid-induced osteomalacia. Cleve Clin J Med 1987;54:214-6. View abstract.
  5. Insogna KL, Bordley DR, Caro JF, Lockwood DH. Osteomalacia and weakness from excessive antacid ingestion. JAMA 1980;244:2544-6. View abstract.
  6. Heaney RP, Nordin BE. Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. J Am Coll Nutr 2002;21:239-44.. View abstract.
  7. Rosen GH, Boullata JI, O'Rangers EA, et al. Intravenous phosphate repletion regimen for critically ill patients with moderate hypophosphatemia. Crit Care Med 1995;23:1204-10. View abstract.
  8. Perreault MM, Ostrop NJ, Tierney MG. Efficacy and safety of intravenous phosphate replacement in critically ill patients. Ann Pharmacother 1997;31:683-8. View abstract.
  9. Duffy DJ, Conlee RK. Effects of phosphate loading on leg power and high intensity treadmill exercise. Med Sci Sports Exerc 1986;18:674-7. View abstract.
  10. Bredle DL, Stager JM, Brechue WF, Farber MO. Phosphate supplementation, cardiovascular function, and exercise performance in humans. J Appl Physiol 1988;65:1821-6. View abstract.
  11. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academy Press, 1999. Available at: http://books.nap.edu/books/0309063507/html/index.html.
  12. Carey CF, Lee HH, Woeltje KF (eds). Washington Manual of Medical Therapeutics. 29th ed. New York, NY: Lippincott-Raven, 1998.
  13. Alvarez-Arroyo MV, Traba ML, Rapado TA, et al. Correlation between 1.25 dihydroxyvitamin D serum levels and fractional rate of intestinal calcium absorption in hypercalciuric nephrolithiasis. Role of phosphate. Urol Res 1992;20:96-7. View abstract.
  14. Heaton KW, Lever JV, Barnard RE. Osteomalacia associated with cholestyramine therapy for post-ileectomy diarrhea. Gastroenterology 1972;62:642-6. View abstract.
  15. Becker GL. The case against mineral oil. Am J Digestive Dis 1952;19:344-8. View abstract.
  16. Schwarz KB, Goldstein PD, Witztum JL, et al. Fat-soluble vitamin concentrations in hypercholestrolemic children treated with colestipol. Pediatrics 1980;65:243-50. View abstract.
  17. West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut 1975;16:93-8. View abstract.
  18. Spencer H, Menaham L. Adverse effects of aluminum-containing antacids on mineral metabolism. Gastroenterology 1979;76:603-6. View abstract.
  19. Roberts DH, Knox FG. Renal phosphate handling and calcium nephrolithiasis: role of dietary phosphate and phosphate leak. Semin Nephrol 1990;10:24-30. View abstract.
  20. Harmelin DL, Martin FR, Wark JD. Antacid-induced phosphate depletion syndrome presenting as nephrolithiasis. Aust NZ J Med 1990;20:803-5. View abstract.
  21. Yates AA, Schlicker SA, Suitor CW. Dietary reference intakes: The new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J Am Diet Assoc 1998;98:699-706. View abstract.
  22. Fauci AS, Braunwald E, Isselbacher KJ, et al. Harrison's Principles of Internal Medicine, 14th ed. New York, NY: McGraw-Hill, 1998.
  23. Shils ME, Olson JA, Shike M, Ross AC, eds. Modern Nutrition in Health and Disease. 9th ed. Baltimore, MD: Williams & Wilkins, 1999.
  24. Galloway SD, Tremblay MS, Sexsmith JR, Roberts CJ. The effects of acute phosphate supplementation in subjects of different aerobic fitness levels. Eur J Appl Physiol Occup Physiol 1996;72:224-30. View abstract.
  25. Helikson MA, Parham WA, Tobias JD. Hypocalcemia and hyperphosphatemia after phosphate enema use in a child. J Pediatr Surg 1997;32:1244-6. View abstract.
  26. DiPalma JA, Buckley SE, Warner BA, et al. Biochemical effects of oral sodium phosphate. Dig Dis Sci 1996;41:749-53. View abstract.
  27. Fine A, Patterson J. Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature. Am J Kidney Dis 1997;29:103-5. View abstract.
  28. Clarkston WK, Tsen TN, Dies DF, et al. Oral sodium phosphate versus sulfate-free polyethylene glycol electrolyte lavage solution in outpatient preparation for colonoscopy: a prospective comparison. Gastrointest Endosc 1996;43:42-8. View abstract.
  29. Hill AG, Teo W, Still A, et al. Cellular potassium depletion predisposes to hypokalaemia after oral sodium phosphate. Aust N Z J Surg 1998;68:856-8. View abstract.
  30. Heller HJ, Reza-Albarran AA, Breslau NA, Pak CY. Sustained reduction in urinary calcium during long-term treatment with slow release neutral potassium phosphate in absorptive hypercalciuria. J Urol 1998;159:1451-5; discussion 1455-6. View abstract.
  31. Hardman JG, Limbird LL, Molinoff PB, eds. Goodman and Gillman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996.
  32. Young DS. Effects of Drugs on Clinical Laboratory Tests 4th ed. Washington: AACC Press, 1995.
  33. McKevoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
  34. Monographs on the medicinal uses of plant drugs. Exeter, UK: European Scientific Co-op Phytother, 1997.
Show more references
Show fewer references
Last reviewed - 08/22/2012




Page last updated: 27 October 2014